In recent years, studies of combination strategies utilizing
the extended release (XL) formulation of bupropion have become
increasingly popular with community psychiatrists, in part
because of a more favorable and benign side-effect profile and
its selective capacity to modulate NE and DA neurotransmitter
levels while offsetting other monoamines specifically as a result
of increased serotonergic neurotransmission.